Regional anaesthesia and thromboembolism prophylaxis/anticoagulation: Revised guidelines of the German Society of Anaesthesiology and Intensive Care Medicine;Rückenmarksnahe regionalanästhesien und thromboembolieprophylaxe/antithrombotische medikation: Überarbeitete leitlinien der Deutschen Gesellschaft für Anästhesiologie und Intensivmedizin

Anasthesiologie und Intensivmedizin

Volumn 44, Issue 3, 2003, Pages 218-230

  Gogarten, W ^a   Van Aken, H ^a   Buttner J ^b   Riess, H ^c   Wulf, H ^d   Buerkle, Hartmut ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b Abteilung fur Anasthesie   (Germany)

^c HUMBOLDT UNIVERSITY   (Germany)

^d PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Acetylsalicylic acid; Anticoagulants; Clopidogrel; Danaproid; Epidural anaesthesia; Fondaparinux; Haematoma; Heparin; Hirudin; Low molecular weight heparin; Prophylaxis; Spinal anaesthesia; Thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; LOW MOLECULAR WEIGHT HEPARIN;

ANESTHESIOLOGY; ANTICOAGULATION; BLEEDING; CATHETER; EPIDURAL HEMATOMA; GERMANY; HEMOSTASIS; HUMAN; INTENSIVE CARE; POSTOPERATIVE COMPLICATION; PRACTICE GUIDELINE; PROPHYLAXIS; REGIONAL ANESTHESIA; REVIEW; SAFETY; SPINE; THROMBOEMBOLISM;

EID: 0037345662     PISSN: 01705334     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Aiach M, Michaud A, Balian JL, Lefebvre M, Woler M, Fourtillan J: A new low molecular weight heparin derivative. Thromb Res 1983, 31: 611
2. Bacher P, Welzel D, Iqbal O, Hoppensteadt D, Callas D, Walenga JM, Fareed J: The thrombolytic potency of LMW-heparin compared to urokinase in a rabbit jugular vein clot lysis model. Thromb Res 1992, 66: 151
3. Basic-Micic M, Breddin HK: Effects of unfractionated and low molecular weight heparin on platelet-induced thrombin formation time and platelet adhesion. Semin Thromb Hemost 1993, 19: 22
4. Bergquist D, Lindblad B, Mätzsch T: Risk of combining low molecular weight heparin for thromboprophylaxis and epidural or spinal anesthesia. Sem Thromb Hemost 1993, 19: 147
5. Bhatt DL, Topol EJ: Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. JAMA 2000, 284: 1549
6. Boneu B, Necciari J, Cariou R, Sié P, Gabaig AM, Kieffer G, Dickinson J, Lamond G, Moelker H, Mant T, Magnani H: Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/ORG31540) with high affinity to antithrombin III in man. Thromb Haemost 1995, 74: 1468
7. Brown DL, Farm CSJ, Chang CJ: Meta-analysis of effectiveness and safety of abciximab versus eptifibatide or tirofiban in percutaneous coronary intervention. Am J Cardiol 2001, 87: 537
8. Buur T, Larsson R, Berglund U, Donat F, Tronquet C: Pharmacokinetics and effect of ticlopidine on platelet aggregation in subjects with normal and impaired renal function. J-Clin-Pharmacol 1997, 37: 108
9. Caprie Steering Committee: A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996, 348: 1329
10. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, Vyas SN, FitzGerald GA: Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001, 345: 1809
11. Chaney MA: Intrathecal and epidural anesthesia and analgesia for cardiac surgery. Anesth Analg 1997, 84: 1211
12. CLASP: A randomized trial of low dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. Lancet 1994, 343: 619
13. Coller BS: Anti-GPIIb/IIIa drugs: Current strategies and future directions. Thromb Haemost 2001, 86: 427
14. Cronberg S, Wallmark E, Soderberg I: Effect on platelet aggregation of oral administration of 10 non-steroidal analgesics to humans. Scand J Haematol 1984, 33: 155
15. Danhof M, de Boer A, Magnani HN, Stiekema JCJ: Pharmacokinetic considerations on Orgaran (Org 10172) therapy. Haemostasis 1992, 22: 73
16. Denninger MH, Necciari J, Serre-Lacroix E, Sissmann J: Clopidogrel antiplatelet activity is independent of age and presence of atherosclerosis. Sem Thromb Hemost 1999, 25(Suppl 2): 41
17. Encke A: Leitlinien zur stationären und ambulanten Thromboembolie-Prophylaxe in der Chirurgie. Expertengespräche zur Thromboembolie-Prophylaxe 1997 und 2000. Deutsche Gesellschaft für Chirurgie 2000, 3: G91
18. Enneking FK, Benzon H: Oral anticoagulants and regional anesthesia: a perspective. Reg Anesth Pain Med 1998, 23(Suppl 2): 140
19. Eriksson BI, Arfwidsson AC, Frison L, Eriksson UG, Bylock A, Kälebo P, Fager G, Gustafsson D: A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. Thromb Haemost 2002, 87: 231
20. Eriksson BI, Bergquist D, Kälebo P, Dahl OE, Lindbratt S, Bylock A, Frison L, Eriksson UG: Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomized trial. Lancet 2002, 360: 1441
21. Eriksson BI, Ekman S, Kälebo P, Zachrisson B, Bach D, Close P: Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393. Lancet 1996, 347: 635
22. Eriksson BI, Ögren M, Eriksson UG, Kälebo P, Ahnfelt L, Björkström S, Sjötedt Å, Folestadt A, Arfwidsson AC, Elvander CS, Frison L: Prophylaxis of venous thromboembolism with subcutaneous melagatran in total hip or total knee replacement: results from Phase II studies. Thromb Res 2002, 105: 371.
23. Eriksson BI, Wille-Jorgensen P, Kälebo P, Mouret P, Rosencher N, Bösch P, Baur M, Ekman S, Bach D, Lindbratt S, Close P: A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 1997, 337: 1329
24. Eriksson H, Eriksson UG, Frison L, Hansson PO, Held P, Holmström M, Hägg A, Jonsson T, Lapidus L, Leijd N, Stockelberg D, Säfwenberg U, Taghavi A: Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT. Thromb Haemost 1999, 81: 358
25. Geerts WH, Jay RM, Code KI, Chen E, Szalai JP, Saibil EA, Hamilton PA: A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma. N Engl J Med 1996, 335: 701
26. Gibbs NM, Weightman WM, Thrackray NM, Michaelopoulos N, Weidmann C: The effects of recent aspirin ingestion on platelet function in cardiac surgical patients. Eur J Anaesthesiol 2001, 15: 55
27. Gogarten W, Van Aken H, Wulf H, Klose R, Vandermeulen E, Harenberg J: Rückenmarksnahe Regionalanästhesien und Thromboembolieprophylaxe/Antikoagulation. Anästh Intensivmed 1997, 12: 623
28. Haas S, Flosbach CW: Prevention of postoperative thromboembolism with enoxaparin in general surgery: a german multicenter trial. Sem Thromb Hemost 1993, 19(Suppl. 1): 164
29. Harenberg J, Huisman MV, Tolle AR, Breddin HK, Kirchmaier CM: Reduction in thrombus extension and clinical end points in patients after initial treatment for deep vein thrombosis with the fixed-dose body weight-independent low molecular weight heparin certoparin. Semin Thromb Hemost 2001, 27: 513
30. Harrington RA, Armstrong PW, Graffagnino C, Van de Werf F, Kereiakes DJ, Sigmon KN, Card T, Joseph DM, Samuels R, Granett J, Chan R, Califf RM, Topol E: Investigators for the Anti-Platelet Useful Dose (APLAUD) Study Investigators: Dose-finding, safety, and tolerabaility study of an oral platelet glycoprotein IIb/IIIa inhibitor, lotrafiban, in patients with coronary or cerebral atherosclerotic disease. Circulation 2000, 102: 728
31. Horlocker TT, Wedel DJ: Neuraxial block and low-molecular-weight heparin: Balancing perioperative analgesia and thromboprophylaxis. Reg Anesth Pain Med 1998, 23(Suppl 2): 164
32. Horlocker TT, Wedel DJ, Offord KP: Does preoperative antiplatelet therapy increase the risk of hemorrhagic complications associated with regional anesthesia? Anesth Analg 1990, 70: 631
33. Horlocker TT, Wedel DJ, Schlichting JL: Postoperative epidural analgesia and oral anticoagulant therapy. Anesth-Analg 1994, 79: 89
34. Horlocker TT, Wedel DJ, Schroeder DR, Rose SH, Elliott BA, McGregor DG, Wong GY: Preoperative antiplatelet therapy does not increase the risk of spinal hematoma associated with regional anesthesia. Anesth-Analg 1995, 80: 303
35. Imperiale TF, Speroff T: A meta-analysis of methods to prevent venous thromboembolism following total hip replacement. JAMA 1994, 271: 1780
36. Januzzi JL, Jang I-K: Heparin induced thrombocytopenia: diagnosis and contemporary antithrombin management. J Thromb Thrombolysis 1999, 7: 259
37. Kaluza GL, Joseph J, Lee JR, Raizner ME, Raizner AE: Catastropic outcomes of noncardiac surgery soon after coronary stenting. J Am Coll Cardiol 2000, 35: 1288
38. Lassen MR, Bauer KA, Eriksson BI, Turpie AGG, for the European Pentasaccharide HIP Elective Surgery Study (EPHESUS) Steering Committee: Postoperative fondaparinux verus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomized double-blind comparison. Lancet 2002, 359: 1715
39. Lawton MT, Porter RW, Heiserman JE, Jacobowitz R, Sonntag VKH, Dickman CA: Surgical management of spinal epidural hematoma: relationship between surgical timing and neurological outcome. J Neurosurg 1995, 83: 1
40. Odoom JA, Sih IL: Epidural analgesia and anticoagulant therapy. Experience with one thousand cases of continuous epidurals. Anaesthesia 1983, 38: 254
41. Poidevin P, Salome V, Riegel B, Verdin MF, Bernard A, Krivosic-Horber R: [Recombinant hirudin in neurosurgery]. Ann Fr Anesth Reanim 2001, 20: 570
42. Pulmonary Embolism Prevention (PEP) Trial Collaborative Group: Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: pulmonary embolism prevention (PEP). Lancet 2000, 355: 1295
43. Rao TKL, El-Etr AA: Anticoagulation following placement of epidural and subarachnoid catheters: an evaluation of neurologic sequelae. Anesthesiology 1981, 55: 618
44. Ruff RR, Dougherty JH: Complications of lumbar puncture followed by anticoagulation. Stroke 1981, 12: 879
45. Sanofi-Synthelabo: Data on file. 2002
46. Schmidt A, Nolte H: Subdurale und epidurale Hämatome nach rückenmarksnahen Regionalanästhesien. Anaesthesist 1992, 41: 276
47. Schnitzer TJ: Cyclooxygenase-2-specific inhibitors: are they safe? Am J Med 2001, 110: S46
48. Schroeder DR: Statistics: Detecting a rare adverse drug reaction using spontaneous reports. Reg Anesth Pain Med 1998, 23(Suppl 2): 183
49. Schrör K: Antiplatelet drugs. A comparative review. Drugs 1995, 50: 7
50. Sharis PJ, Cannon CP, Loscalzo J: The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med 1998, 129: 394
51. Stafford-Smith M: Impaired haemostasis and regional anaesthesia. Can J Anaesth 1996, 43: R129
52. TIFDED Study Group: Thromboprophylaxis in hip fracture surgery: a pilot study comparing danaparoid, enoxaparin and dalteparin. Haemostasis 1999, 29: 310
53. Tryba M: Rückenmarksnahe Regionalanästhesie und niedermolekulare Heparine: Pro. Anästhesiol Intensivmed Notfallmed Schmerzther 1993, 28:179
54. Turpie AGG, Gallus AS, Hoek JA: A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 2001, 344: 619
55. Urmey WF, Rowlingson J: Do antiplatelet agents contribute to the development of perioperative spinal hematoma? Reg Anesth Pain Med 1998, 23: 146
56. Vandermeulen E: Is anticoagulation and central neural blockade a safe combination? Curr Opin Anaesthesiol 1999, 12: 539
57. Vandermeulen E, Gogarten W, Van Aken H: Risiken und Komplikationsmöglichkeiten der Periduralanästhesie. Anaesthesist 1997, 46: 179
58. Vandermeulen EP: Central nerve blocks and anticoagulants. In: Martin E, Nawroth P (Hrsg) Fachübergreifende Aspekte der Hamostaseologie II Springer Verlag Berlin 1997
59. Vandermeulen EP, Van Aken H, Vermylen J: Anticoagulants and spinal-epidural anesthesia. Anesth Analg 1994, 79: 1165
60. Verstraete M, Nurmohamed M, Kienast J, Siebeck M, Silling-Engelhardt G, Büller H, Hoet B, Bichler J, Close P: Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. J Am Coll Cardiol 1993, 22: 1080
61. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG: Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. New Engl J Med 1995, 332: 1331
62. Weaver AL: Rofecoxib: clinical pharmacology and clinical experience. Clin Ther 2001, 23: 1323
63. Weber AA, Schrör K: Pharmakologie von Ticlopidin und Clopidogrel im Vergleich zu Acetylsalicylsäure. Internist 1997, 38: 1115
64. Wulf H: Thromboembolieprophylaxe und rückenmarksnahe Regionalanästhesie. Bericht von der Sitzung des Wissenschaftlichen Arbeitskreises Regionalanästhesie der DGAI. Anästh-Intensivmed 1995, 36: 216
65. Yende S, Wunderink RG: Effect of clopidogrel on bleeding after coronary artery bypass surgery. Crit Care Med 2001, 29: 2271.